Da Hee Han, PharmD

The FDA has approved evolocumab for the prevention of heart attacks.

FDA has cleared the KardiaBand device to recordtheir EKG to detect normal heart rhythms and atrial fibrillation.

The 10 mg dose of rivaroxaban substantially lowered the risk for recurrent venous thromboembolism.

Patients taking antipsychotic agents, especially clozapine, should be monitored regularly for hypertension.

No evidence shows efficacy of PCI procedures for patients with stable coronary artery disease with angina.

Patients with systolic heart failure see physical benefits with sacubitril/valsartan.

Bosentan has been approved for use in pediatric pulmonary arterial hypertension in children aged 3 years or older.

The FDA has approved a new pitavastatin for the treatment of primary hyperlipidemia or mixed dyslipidemia.

The FDA has granted clearance for a new non-invasive acoustic and electrocardiogram device for the detection of physiological and pathological heart murmurs.

Study finds genuine difference between a fixed-dose combination of isosorbide dinitrate plus hydralazine HCl and an off-label combination of the separate generic drugs for the treatment of heart failure in African American patients.